Business
Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above
First ready-to-use liquid glucagon available in a single-dose vial and syringe kit for rescue CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc.
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\nFirst ready-to-use liquid glucagon available in a single-dose vial and syringe kit for rescue\n\n CHICAGO--(BUSINESS WIRE)--\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Gvoke® (glucagon injection) Kit is now available by prescription. Gvoke Kit contains one (1) single-dose sterile syringe with markings for 0.1 mL (0.5 mg pediatric dose) and 0.2 mL (1 mg adult dose), and one single-dose vial containing 0.2 mL of solution.\n\n“We are pleased to offer another ready-to-use rescue form of Gvoke for the millions of people with diabetes at increased risk of a severe low blood sugar event. Gvoke Kit contains the same room-temperature liquid-stable glucagon as in Gvoke HypoPen® and Gvoke® PFS but may be preferred by those who would rather draw up the appropriate rescue dose using a vial and syringe,” said Kevin McCulloch, Xeris’ Chief Commercial Officer. “Awareness of the benefits to patients of having their Gvoke nearby is growing quickly, and we expect availability of Gvoke Kit to add to the growing interest.”\n\nABOUT Gvoke®\n\nGvoke® PFS and Gvoke HypoPen® (glucagon injection), the first prescription, ready-to-use, pre-mixed, pre-measured glucagon injection, were approved by the FDA in September 2019 for use in the United States. Gvoke is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. In August 2021, the FDA approved Gvoke® Kit, the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\n\nINDICATION AND IMPORTANT SAFETY INFORMATION\n\nGVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.\n\nINDICATION AND IMPORTANT SAFETY INFORMATION\n\nGVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.\n\nIMPORTANT SAFETY INFORMATION\n\nContraindications\n\nGVOKE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure, insulinoma because of the risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergi...